BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 15458882)

  • 1. Sequential pathways of testing after first-trimester screening for trisomy 21.
    Platt LD; Greene N; Johnson A; Zachary J; Thom E; Krantz D; Simpson JL; Silver RK; Snijders RJ; Goetzl L; Pergament E; Filkins K; Mahoney MJ; Hogge WA; Wilson RD; Mohide P; Hershey D; MacGregor S; Bahado-Singh R; Jackson LG; Wapner R;
    Obstet Gynecol; 2004 Oct; 104(4):661-6. PubMed ID: 15458882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results.
    Benn PA; Ying J; Beazoglou T; Egan JF
    Prenat Diagn; 2001 Jan; 21(1):46-51. PubMed ID: 11180240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening.
    Maymon R; Cuckle H; Jones R; Reish O; Sharony R; Herman A
    Prenat Diagn; 2005 Dec; 25(12):1102-6. PubMed ID: 16231324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
    Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
    Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers.
    Palomaki GE; Neveux LM; Knight GJ; Haddow JE
    Prenat Diagn; 2003 Mar; 23(3):243-7. PubMed ID: 12627428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester or second-trimester screening, or both, for Down's syndrome.
    Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
    N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First- and second-trimester evaluation of risk for Down syndrome.
    Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
    Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years.
    Biggio JR; Morris TC; Owen J; Stringer JS
    Am J Obstet Gynecol; 2004 Mar; 190(3):721-9. PubMed ID: 15042005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second trimester two-step trisomy 18 screening using maternal serum markers.
    Muller F; Sault C; Lemay C; Roussel-Mizon N; Forestier F; Frendo JL;
    Prenat Diagn; 2002 Jul; 22(7):605-8. PubMed ID: 12124697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Screening for Down syndrome using first-trimester combined screening followed by second trimester ultrasound examination in an unselected population].
    Rozenberg P; Bussières L; Chevret S; Bernard JP; Malagrida L; Cuckle H; Chabry C; Durand-Zaleski I; Bidat L; Lacroix I; Moulis M; Roger M; Jacquemot MC; Bault JP; Boukobza P; Boccara P; Vialat F; Giudicelli Y; Ville Y
    Gynecol Obstet Fertil; 2007 Apr; 35(4):303-11. PubMed ID: 17350315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population.
    Rozenberg P; Bussières L; Chevret S; Bernard JP; Malagrida L; Cuckle H; Chabry C; Durand-Zaleski I; Bidat L; Lacroix I; Moulis M; Roger M; Jacquemot MC; Bault JP; Boukobza P; Boccara P; Vialard F; Giudicelli Y; Ville Y
    Am J Obstet Gynecol; 2006 Nov; 195(5):1379-87. PubMed ID: 16723105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-stage contingent screening for Down syndrome.
    Wright D; Bradbury I; Cuckle H; Gardosi J; Tonks A; Standing S; Benn P
    Prenat Diagn; 2006 Jun; 26(6):528-34. PubMed ID: 16634118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy.
    Palomaki GE; Neveux LM; Haddow JE; Wyatt P
    Prenat Diagn; 2007 Sep; 27(9):808-13. PubMed ID: 17590886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.